The regulation of complementary and alternative medicines in South Africa is a complex and evolving process, with a rich history and ongoing challenges. Dr. Andy Gray delves into this topic, exploring the legal framework, the current state of affairs, and the gaps that remain. This article provides a comprehensive overview, offering insights into the regulatory landscape and the future direction of this critical issue.
The story begins with the concept of 'call-up notices', a legacy of South Africa's medicines legislation dating back to 1965. This system, designed to manage the influx of medicines without proper safety, efficacy, or quality assessments, laid the foundation for the current regulatory framework. By the mid-1980s, a more rigorous process was established, requiring new medicines to be registered before marketing. However, an important exception was made for homoeopathic medicines, which were exempt from full registration but faced strict restrictions on medical claims and labeling.
The scope of complementary medicines was broadened with the introduction of the Allied Health Professions Council of South Africa and the South African Health Products Regulatory Authority (Sahpra). Category D medicines, also known as complementary medicines, are now regulated through a separate website and a risk-based approach to registration. This approach aims to progressively bring all complementary medicines under effective regulation, focusing on those with antiviral properties, diabetes treatment, cardiac conditions, and cancer.
Despite the intention to regulate these medicines, the process has been marred by litigation. The Alliance of Natural Health Products (South Africa) challenged the regulatory scheme, leading to a Supreme Court of Appeal decision in 2022. The court confirmed that Sahpra should not regulate substances and preparations that do not meet the definition of a medicine. This ruling has resulted in draft amendments to the 2017 General Regulations, which have yet to be finalized.
Interestingly, the absence of final regulations does not imply a total lack of control. The initial roadmap has been replaced by guidelines, and manufacturers, wholesalers, or distributors of complementary medicines are required to be licensed by Sahpra. This process, however, relies on attestation and desktop evaluation rather than full Good Manufacturing Practice inspections. Low-risk claims are strictly regulated, and manufacturers of health supplements are only allowed to make these claims, with specific allowable levels and claims for each type of supplement.
The article highlights several gaps in the system. The finalization of regulations after the court challenge is crucial, and a risk-based 'call-up' process needs to be initiated. Moving from an attestation process to confirming compliance with Good Manufacturing Practice standards is essential. Additionally, the proprietary names used for complementary medicines are not pre-approved, and oversight of advertising and marketing practices remains a challenge.
One significant gap is the regulation of African traditional medicines, which are not currently captured by the definition of Category D medicines. Dr. Gray emphasizes the need to address this gap to ensure comprehensive regulatory control. The article concludes by emphasizing the importance of effective oversight and the need to bridge the remaining gaps in the medicines regulatory system.
In summary, the regulation of complementary and alternative medicines in South Africa is a complex journey, with a rich history and ongoing challenges. Dr. Andy Gray's analysis provides a comprehensive overview, offering insights into the regulatory landscape and the future direction of this critical issue.
